^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
VMT-𝛼-NET
i
Other names: VMT-𝛼-NET, 212Pb-VMT-𝛼-NET, [212Pb]VMT-𝛼-NET alpha-particle therapy, [212Pb]VMT-α-NET
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Lantheus, Perspective Therap
Drug class:
Alpha radiation emitter, SSTR agonist
Related drugs:
4ms
212-Pb-VMT: Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (clinicaltrials.gov)
P1/2, N=280, Recruiting, Perspective Therapeutics | N=52 --> 280 | Trial completion date: Jan 2028 --> Dec 2029 | Trial primary completion date: Sep 2026 --> Nov 2029
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
SSTR (Somatostatin Receptor) • CD4 (CD4 Molecule) • SSTR2 (Somatostatin Receptor 2)
|
VMT-𝛼-NET
6ms
Lead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent. (PubMed, Indian J Nucl Med)
As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-α-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-α-NET with Ga-68 DOTANOC.
Journal
|
SSTR (Somatostatin Receptor)
|
VMT-𝛼-NET
7ms
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy (clinicaltrials.gov)
P1/2, N=53, Not yet recruiting, National Cancer Institute (NCI)
New P1/2 trial • Metastases
|
VMT-𝛼-NET
8ms
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors (clinicaltrials.gov)
P1, N=24, Active, not recruiting, David Bushnell | Recruiting --> Active, not recruiting
Enrollment closed
|
VMT-𝛼-NET
1year
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors (clinicaltrials.gov)
P1, N=24, Recruiting, David Bushnell
New P1 trial
|
VMT-𝛼-NET
2years
212-Pb-VMT: Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (clinicaltrials.gov)
P1/2, N=52, Not yet recruiting, Viewpoint Molecular Targeting
New P1/2 trial • Metastases
|
SSTR (Somatostatin Receptor) • CD4 (CD4 Molecule) • SSTR2 (Somatostatin Receptor 2)
|
SSTR2 expression • SSTR2 positive
|
VMT-𝛼-NET
Share via
